• Product sales up 14% to NZ$44.6 million, with Myriad portfolio growing 30%
• Normalised EBITDA profit of NZ$1.8 million, compared to a loss of NZ$1.5 million in H1 FY25
• Reaffirms FY26 guidance of NZ$92-100 million in total revenue and NZ$5-8 million in normalised EBITDA profit

Aroa Biosurgery Limited (AROA) has reported its financial results for the half-year ended 30 September 2025 (H1 FY26). The company maintained a clear focus on improving sales productivity and penetration in existing accounts, which delivered product sales of NZ$44.6 million for the period, representing an increase of 14% (11% on a constant currency basis) over the previous comparable period. This was predominantly driven by the strong performance of the Myriad portfolio, which grew 30% on a constant currency basis. AROA ended H1 FY26 with 380 active accounts, up from 328 at the end of FY25, while average account value also grew 8%. The company continued expanding the clinical evidence base for its AROA ECM technology, with 10 new studies published during the reporting period, bringing the total to 116 peer-reviewed studies. AROA reported four consecutive quarters of positive cash flow and expects to become increasingly cash flow positive over time. The company reaffirmed its FY26 guidance of NZ$92-100 million in total revenue (an increase of 10-20% on FY25 on a constant currency basis) and NZ$5-8 million in normalised EBITDA profit. The company anticipates H2 FY26 total revenue of approximately NZ$47-55 million and normalised EBITDA profit of NZ$3.5-6.5 million.

AROA reaffirms its FY26 guidance of NZ$92-100 million in total revenue (an increase of 10-20% on FY25 on a constant currency basis) and NZ$5-8 million in normalised EBITDA profit.

The company expects H2 FY26 total revenue of approximately NZ$47-55 million and normalised EBITDA profit of NZ$3.5-6.5 million.